Toon Lambrechts1, Ioannis Papantoniou2, Brent Rice3, Jan Schrooten4, Frank P Luyten2, Jean-Marie Aerts5. 1. Prometheus-Division of Skeletal Tissue Engineering, KU Leuven, Belgium; Division Animal and Human Health Engineering, KU Leuven, Belgium. 2. Prometheus-Division of Skeletal Tissue Engineering, KU Leuven, Belgium; Skeletal Biology and Engineering Research Centre, KU Leuven, Belgium. 3. Terumo BCT, Inc., Lakewood, Colorado, USA. 4. Prometheus-Division of Skeletal Tissue Engineering, KU Leuven, Belgium; Department of Materials Engineering, KU Leuven, Belgium. 5. Prometheus-Division of Skeletal Tissue Engineering, KU Leuven, Belgium; Division Animal and Human Health Engineering, KU Leuven, Belgium. Electronic address: jean-marie.aerts@biw.kuleuven.be.
Abstract
BACKGROUND AIMS: With the increasing scale in stem cell production, a robust and controlled cell expansion process becomes essential for the clinical application of cell-based therapies. The objective of this work was the assessment of a hollow fiber bioreactor (Quantum Cell Expansion System from Terumo BCT) as a cell production unit for the clinical-scale production of human periosteum derived stem cells (hPDCs). METHODS: We aimed to demonstrate comparability of bioreactor production to standard culture flask production based on a product characterization in line with the International Society of Cell Therapy in vitro benchmarks and supplemented with a compelling quantitative in vivo bone-forming potency assay. Multiple process read-outs were implemented to track process performance and deal with donor-to-donor-related variation in nutrient needs and harvest timing. RESULTS: The data show that the hollow fiber bioreactor is capable of robustly expanding autologous hPDCs on a clinical scale (yield between 316 million and 444 million cells starting from 20 million after ± 8 days of culture) while maintaining their in vitro quality attributes compared with the standard flask-based culture. The in vivo bone-forming assay on average resulted in 10.3 ± 3.7% and 11.0 ± 3.8% newly formed bone for the bioreactor and standard culture flask respectively. The analysis showed that the Quantum system provides a reproducible cell expansion process in terms of yields and culture conditions for multiple donors.
BACKGROUND AIMS: With the increasing scale in stem cell production, a robust and controlled cell expansion process becomes essential for the clinical application of cell-based therapies. The objective of this work was the assessment of a hollow fiber bioreactor (Quantum Cell Expansion System from Terumo BCT) as a cell production unit for the clinical-scale production of human periosteum derived stem cells (hPDCs). METHODS: We aimed to demonstrate comparability of bioreactor production to standard culture flask production based on a product characterization in line with the International Society of Cell Therapy in vitro benchmarks and supplemented with a compelling quantitative in vivo bone-forming potency assay. Multiple process read-outs were implemented to track process performance and deal with donor-to-donor-related variation in nutrient needs and harvest timing. RESULTS: The data show that the hollow fiber bioreactor is capable of robustly expanding autologous hPDCs on a clinical scale (yield between 316 million and 444 million cells starting from 20 million after ± 8 days of culture) while maintaining their in vitro quality attributes compared with the standard flask-based culture. The in vivo bone-forming assay on average resulted in 10.3 ± 3.7% and 11.0 ± 3.8% newly formed bone for the bioreactor and standard culture flask respectively. The analysis showed that the Quantum system provides a reproducible cell expansion process in terms of yields and culture conditions for multiple donors.
Authors: Amanda Mizukami; Mario Soares de Abreu Neto; Francisco Moreira; Ana Fernandes-Platzgummer; Yi-Feng Huang; William Milligan; Joaquim M S Cabral; Cláudia L da Silva; Dimas T Covas; Kamilla Swiech Journal: Stem Cell Rev Rep Date: 2018-02 Impact factor: 5.739
Authors: Antalya Ho-Shui-Ling; Johanna Bolander; Laurence E Rustom; Amy Wagoner Johnson; Frank P Luyten; Catherine Picart Journal: Biomaterials Date: 2018-07-11 Impact factor: 12.479
Authors: Muhammad Najib Fathi Bin Hassan; Muhammad Dain Yazid; Mohd Heikal Mohd Yunus; Shiplu Roy Chowdhury; Yogeswaran Lokanathan; Ruszymah Bt Hj Idrus; Angela Min Hwei Ng; Jia Xian Law Journal: Stem Cells Int Date: 2020-07-15 Impact factor: 5.443